Mpox vaccine shows promise for teens in new study
NCT ID NCT05740982
First seen Apr 24, 2026 · Last updated May 22, 2026 · Updated 8 times
Summary
This study tested the MVA-BN mpox vaccine in about 315 healthy teens aged 12-17 and compared their immune response to about 211 adults. The goal was to see if the vaccine works as well in teens as it does in adults. Researchers also closely monitored safety, including any side effects like injection site pain or fatigue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MONKEYPOX are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Baylor College of Medicine
Houston, Texas, 77030-3411, United States
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115-6110, United States
-
Children's Hospital of Philadelphia
Philadelphia, Pennsylvania, 19146, United States
-
Children's of Alabama Child Health Research Unit (CHRU)
Birmingham, Alabama, 35233-0011, United States
-
Cincinnati Children's Hospital Medical Center Vaccine Research Center
Cincinnati, Ohio, 45229-3039, United States
-
Duke Vaccine and Trials Unit
Durham, North Carolina, 27703, United States
-
Emory University School of Medicine
Atlanta, Georgia, 30322-1014, United States
-
George Washington University Medical Faculty Associates
Washington D.C., District of Columbia, 20037, United States
-
Kaiser Permanente Washington Health Research Institute
Seattle, Washington, 98101-1466, United States
-
NIH Clinical Research Center, Investigational Drug Management and Research Section
Bethesda, Maryland, 20892-1504, United States
-
Ponce Medical School Foundation Inc., CAIMED Center
Ponce, 00716, Puerto Rico
-
Saint Louis University Center for Vaccine Development
St Louis, Missouri, 63104-1015, United States
-
UPMC University Center
Pittsburgh, Pennsylvania, 15213, United States
-
University of Maryland, School of Medicine, Center for Vaccine Development and Global Health
Baltimore, Maryland, 21201-1509, United States
-
University of Rochester Medical Center
Rochester, New York, 14642-0001, United States
-
University of Texas Medical Branch
Galveston, Texas, 77555-0435, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37212, United States
-
Washington University in St. Louis
St Louis, Missouri, 63110-1010, United States
Conditions
Explore the condition pages connected to this study.